“Global Migraine Drugs market is anticipated to surpass USD 7 Bn by 2030”

16 October 2019

Visiongain has launched a new pharma report ‘Migraine Drugs Market Report 2020-2030’’ by Product Type (Acute Migraine Treatment, Preventive Migraine Treatment), Route of Administration (Oral, Injection, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), and Geography.

Global Migraine Drugs market is anticipated to grow on account of the growing prevalence of migraine. The global Migraine Drugs market is anticipated to grow at a lucrative CAGR of 12.4% and anticipated to surpass USD 7 Billion by 2030.

Migraine is highly common and ranked as the world's third most common disease. Nearly 1 in 4 U.S. families are suffering from migraine, although the effect on females is overwhelmingly weighted: 85% of chronic migraine sufferers are females. Most individuals are affected by migraine once or twice a month, however, chronic migraine has more than 4 million individuals. Migraine not only leads to substantial costs on people and society but is also associated with a reduced quality of life, often leading to lost job and family life being interrupted. Migraine also increases the danger of asthma, stroke, anxiety, and depression, as well as other pain disorders.

In the United States, the medical cost of chronic migraine treatment was over USD 5.4 billion in the year 2015. Overall, it is anticipated that combined annual health care and lost migraine-related productivity expenses are as large as USD 36 billion.

The growing prevalence of migraine is boosting the growth of migraine drug markets across the globe. Also, the growing female population and increasing awareness among patients associated with migraine prevention and treatment are important factors owing to market growth. Nevertheless, migraine-related side effects are a factor that hinders the market growth. On the contrary, it is anticipated that the existence of growth prospects in emerging nations will provide important players with fresh opportunities.

The U.S. dominated the market with more than 45% share in 2018 and is anticipated to maintain its position until the first half of the forecast period. Launch of calcitonin gene-related peptide (CGRP) based therapies, increasing adoption of novel therapeutics, high prevalence, and a large patient pool in the U.S. are some of the major factors contributing to the growth of migraine drugs market in the region. Emerging economies in the Asia Pacific are being driven by low-cost production of drugs, increasing healthcare expenditure, a large underserved patient pool, and growing disease awareness among other prominent factors.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global migraine drugs market. Companies are also increasing their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Abbott Laboratories, Aegis Therapeutics, LLC., Allergan, Amgen, Astrazeneca PLC, Eli Lilly & Company, Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., Novartis International AG, Pfizer, Sanofi SA, and Teva Pharmaceutical Industries Limited among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022


Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022


Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022


Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022